Semaglutide vs Adipotide

Semaglutide and Adipotide represent two divergent approaches to metabolic research. Semaglutide is a well-characterized GLP-1 receptor agonist with FDA approval for type 2 diabetes, weight management, and non-cirrhotic MASH, supported by large-scale clinical trials. Adipotide (FTPP) is a chimeric peptidomimetic that selectively destroys blood vessels supplying white adipose tissue, inducing rapid fat loss in preclinical models. However, its development was discontinued due to reversible kidney toxicity in primates. This comparison highlights their distinct mechanisms, evidence bases, dosing protocols, and safety profiles, enabling researchers to assess which peptide aligns with specific study objectives.

Semaglutide is a synthetic GLP-1 receptor agonist with 94% sequence homology to human GLP-1, a molecular weight of ~4113.6 g/mol, and the formula C187H291N45O59. It is FDA-approved under brand names Ozempic (type 2 diabetes), Wegovy (chronic weight management), and for non-cirrhotic MASH. Developed by Novo Nordisk and first approved in December 2017, its evidence base includes the STEP and SUSTAIN trial programs involving thousands of patients. Research indicates that semaglutide promotes significant weight loss, improves glycemic control, and reduces cardiovascular risk. No generic version exists, and the FDA has issued warnings about counterfeit products. Its mechanism involves GLP-1 receptor activation, which enhances insulin secretion, delays gastric emptying, and reduces appetite.

Adipotide (FTPP) is a chimeric peptidomimetic (~3,200 g/mol) composed of a prohibitin-targeting domain (CKGGRAKDC) linked to a proapoptotic domain D(KLAKLAK)2. It selectively targets and destroys blood vessels supplying white adipose tissue, leading to rapid fat loss via vascular disruption and adipocyte death. In rhesus monkeys, studies indicate that Adipotide produced an 11% weight loss over 4 weeks, with improvements in metabolic parameters such as insulin sensitivity. However, clinical development was discontinued due to reversible kidney toxicity observed in all primate studies, attributed to prohibitin expression in kidney proximal tubule cells causing off-target damage. Elevated BUN and creatinine levels were noted during treatment but reversed after discontinuation. This peptide is thus limited to preclinical research contexts.

Semaglutide and Adipotide target distinct research areas with minimal overlap. Semaglutide is primarily studied in weight management, metabolic health, and cardiovascular research, leveraging its GLP-1 receptor agonism to explore appetite regulation, glucose homeostasis, and cardioprotective effects. Adipotide, in contrast, is confined to body composition research, focusing on selective adipose tissue reduction through vascular targeting. While both peptides can be used to investigate metabolic pathways, their mechanisms and safety profiles dictate different experimental designs: semaglutide suits long-term metabolic studies, whereas Adipotide is relevant for acute fat loss models or vascular-targeting strategies.

Semaglutide safety is well-documented from large trials. Common adverse effects (≥5% incidence) include nausea, vomiting, diarrhea, abdominal pain, and constipation, which are typically dose-dependent and transient. Additional effects include upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, and tiredness. Serious but rare risks include pancreatitis, gallbladder disease, and severe allergic reactions (e.g., hives, swelling, difficulty breathing). In contrast, Adipotide carries a critical safety concern: reversible kidney toxicity observed in all primate studies. This arises from prohibitin expression in kidney proximal tubule cells, causing off-target damage. Elevated BUN and creatinine levels occur during treatment but reverse after discontinuation. Researchers must weigh these risks when selecting peptides for specific study designs.